Subscribe To
ENTX / Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript
ENTX News
By Zacks Investment Research
May 5, 2023
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. more_horizontal
By Zacks Investment Research
March 31, 2023
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022. more_horizontal
By Zacks Investment Research
February 2, 2023
Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day. more_horizontal
By Zacks Investment Research
January 25, 2023
Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day. more_horizontal
By 24/7 Wall Street
November 23, 2022
Centillion Fund Inc. Ups Stake in Entera Bio (ENTX)
Fintel reports that Centillion Fund Inc. more_horizontal
By Benzinga
July 18, 2022
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-bl more_horizontal
By Seeking Alpha
May 18, 2022
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript
Entera Bio Ltd. (NASDAQ:ENTX ) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Spiros Jamas - Chief Executive Officer Mi more_horizontal
By Seeking Alpha
March 8, 2022
Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript
Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript more_horizontal